Asana Bio Group

Asana Bio Group, through its operating subsidiary Asana BioSciences, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies. Based in Lawrenceville, New Jersey, the company maintains a diverse pipeline targeting indications in oncology, dermatology, and autoimmune diseases. Its lead clinical candidate, gusacitinib (ASN002), is a potent dual JAK/SYK inhibitor being evaluated for the treatment of moderate-to-severe atopic dermatitis and chronic hand eczema. Other key programs include ASN001, a next-generation CYP17 inhibitor for prostate cancer, and ASN007, an ERK inhibitor for solid tumors. Asana leverages a lean, efficient development model to advance its portfolio of small molecules and antibody-drug conjugates. The company was founded by industry veterans with a track record of success in drug development and commercialization.